Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06340711 · ClinicalTrials.gov registry record · Phase 2

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

A Phase 2 study of Gastric Adenocarcinoma and Esophageal Adenocarcinoma, sponsored by Weill Medical College of Cornell University.

Recruiting
Registry status
Phase 2
Development phase
27
Enrollment target
1
Study location

NCT06340711 is a Phase 2 study of Gastric Adenocarcinoma and Esophageal Adenocarcinoma that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 27 participants, below the 245-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06340711, a Phase 2 study of Gastric Adenocarcinoma and Esophageal Adenocarcinoma, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.

RECRUITING
Registry status
Phase 2
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to learn about of the research study drug, telomelysin (OBP-301), in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer. The main question it aims to answer is whether this combination is safe and effective in this type of cancer. Participants will receive 5 injections of OBP-301, approximately every 2 weeks. OBP-301 will be injected directly into the tumor during an esophagogastroduodenoscopy (EGD). At the same time as the injection, a tumor biopsy will be taken. Participants will also receive pembrolizumab infusions every 6 weeks until disease progression or for a maximum of two years. Pembrolizumab infusions will occur on different days than OBP-301 injections.

Conditions Studied

Gastric Adenocarcinoma Esophageal Adenocarcinoma Gastroesophageal Junction Adenocarcinoma

Interventions

  • DRUG Pembrolizumab
  • DRUG OBP-301

Study Locations (1)

New York

  • Weill Cornell Medicine/NewYork-Presbyterian Hospital - New York

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2024-04-25
Est. Completion 2028-04
Phase Phase 2

Sponsor

Weill Medical College of Cornell University

701 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06340711

The ClinicalTrials.gov registry entry for NCT06340711 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (89% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Gastric Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT06340711 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06340711 about?

NCT06340711 is a clinical study titled "Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma". The goal of this study is to learn about of the research study drug, telomelysin (OBP-301), in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer. The main question it aims to answer is whether this combination is safe and effective in this typ...

What is the current status of trial NCT06340711?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2024-04-25. Estimated completion is 2028-04.

What conditions does trial NCT06340711 study?

This clinical trial studies the following conditions: Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma.

What interventions are being tested in trial NCT06340711?

The interventions under investigation include: Pembrolizumab (DRUG), OBP-301 (DRUG).

Who is sponsoring clinical trial NCT06340711?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06340711 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Adenocarcinoma

All registered trials for this condition

Esophageal Adenocarcinoma

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.